- Home
- NERV vs MCVT Comparison
NERV vs MCVT Comparison
Compare NERV & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- MCVT
- Stock Information
- Founded
- NERV 2007
- MCVT 2007
- Country
- NERV United States
- MCVT United States
- Employees
- NERV N/A
- MCVT N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- MCVT Finance Companies
- Sector
- NERV Health Care
- MCVT Finance
- Exchange
- NERV Nasdaq
- MCVT Nasdaq
- Market Cap
- NERV 10.3M
- MCVT 9.3M
- IPO Year
- NERV 2014
- MCVT N/A
- Fundamental
- Price
- NERV $1.78
- MCVT $1.45
- Analyst Decision
- NERV Hold
- MCVT
- Analyst Count
- NERV 1
- MCVT 0
- Target Price
- NERV $5.00
- MCVT N/A
- AVG Volume (30 Days)
- NERV 18.1K
- MCVT 30.1K
- Earning Date
- NERV 05-05-2025
- MCVT 05-15-2025
- Dividend Yield
- NERV N/A
- MCVT N/A
- EPS Growth
- NERV N/A
- MCVT N/A
- EPS
- NERV 0.19
- MCVT 0.18
- Revenue
- NERV N/A
- MCVT $3,301,119.00
- Revenue This Year
- NERV N/A
- MCVT N/A
- Revenue Next Year
- NERV N/A
- MCVT N/A
- P/E Ratio
- NERV $9.00
- MCVT $8.22
- Revenue Growth
- NERV N/A
- MCVT 0.07
- 52 Week Low
- NERV $1.15
- MCVT $1.13
- 52 Week High
- NERV $3.69
- MCVT $3.88
- Technical
- Relative Strength Index (RSI)
- NERV 59.64
- MCVT 39.70
- Support Level
- NERV $1.52
- MCVT $1.36
- Resistance Level
- NERV $1.81
- MCVT $1.51
- Average True Range (ATR)
- NERV 0.17
- MCVT 0.12
- MACD
- NERV 0.04
- MCVT 0.02
- Stochastic Oscillator
- NERV 95.45
- MCVT 55.17
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.